Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05130567 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05130567 · ClinicalTrials.gov record · last posted 2025-04-03

A Study of LP-128 Capsules in Healthy Subjects

StatusActive, Not Recruiting
PhasePhase 1
Started2021-11-19
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LP-128 Capsules After Single- and Multiple-Dose in Healthy Subjects

Amendment record 7 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 7 times since 2021-11-21; most recent amendment 2025-03-31. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-02-26
Status change Recruiting→Active, Not Recruitingv6
2021-12-27
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05130567
Lead Sponsor Guangzhou Lupeng Pharmaceutical Company LTD.
Conditions Chronic Hepatitis b
Enrollment 104 participants
Start Date 2021-11-19
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-03